The European Research Initiative on Anaplastic lymphoma kinase (ALK)-related malignancies (ERIA) celebrated the twentieth anniversary of the discovery of ALK at its annual meeting in Monza on June 20-21, 2014. The meeting was attended by Prof Tom Look (Dana Faber Institute, Harvard), the co-discoverer of the fusion gene NPM-ALK in lymphomas, and Dr. Robert Ghelfi (Pfizer), who developed the first compound to inhibit ALK, crizotinib.
The main task of the European Research Initiative on Anaplastic lymphoma kinase (ALK)-related malignancies (ERIA) is to strengthen cooperation and partnership of research groups focused on the role of ALK in cancer in order to accelerate scientific progress. With this aim in mind we anticipate that more efficacious and less toxic therapeutic strategies will be developed in the future through intense cooperation of involved partners.
| Attachment | Size |
|---|---|
 scientific_programme_2014.pdf | 84.57 KB |